Diabetes mellitus type 2
Reading File
Finding Sources
Searching PubMed
"type 2 diabetes mellitus"[MeSH Terms] AND "management"[MeSH Terms]
Searching the Web
type 2 diabetes mellitus 2025 guidelines management overview
Reading File
Reading File
Searching PubMed
"type 2 diabetes"[MeSH Terms] AND "treatment"[MeSH Terms]
Reading File
Finding Sources
I now have comprehensive material from Harrison's 22nd Edition (2025) and Katzung's Pharmacology 16th Edition. Let me compile a thorough, well-organized answer.
Diabetes Mellitus Type 2 - Comprehensive Overview
Definition & Epidemiology
Type 2 diabetes mellitus (T2DM) is a heterogeneous metabolic disorder characterized by tissue resistance to insulin combined with a relative deficiency in insulin secretion. The endogenous insulin produced is sufficient to prevent ketoacidosis but insufficient to prevent hyperglycemia. It accounts for ~90-95% of all diabetes cases globally.
Risk factors include obesity (particularly central adiposity), physical inactivity, family history, advancing age, prior gestational diabetes, and belonging to certain ethnic groups (South Asian, Black, Hispanic).
Pathophysiology
T2DM develops from two interrelated defects:
-
Insulin resistance - Peripheral tissues (skeletal muscle, liver, adipose) respond poorly to insulin. The liver continues gluconeogenesis inappropriately. Adipose tissue releases excess free fatty acids, worsening insulin resistance.
-
Beta-cell dysfunction - Initially, the pancreas compensates for insulin resistance by increasing insulin output. Over time, beta cells fail progressively - this is the central driver of disease progression, ultimately requiring pharmacologic and often insulin therapy.
Individuals may have more of one defect than the other; the glucose abnormalities may be mild or severe. The condition is progressive, and most patients eventually require multiple agents or insulin.
Diagnostic Criteria
The following criteria establish the diagnosis (any one is sufficient if confirmed on repeat testing, or if symptoms + random glucose are present):
| Criterion | Normal | Prediabetes | Diabetes |
|---|---|---|---|
| Fasting plasma glucose | <100 mg/dL | 100-125 mg/dL (IFG) | ≥126 mg/dL |
| 2-hr post 75g OGTT | <140 mg/dL | 140-199 mg/dL (IGT) | ≥200 mg/dL |
| HbA1c | <5.7% | 5.7-6.4% | ≥6.5% |
| Random glucose + symptoms | - | - | ≥200 mg/dL |
Symptoms (polyuria, polydipsia, unexplained weight loss) + random glucose ≥200 mg/dL are diagnostic without further testing.
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
Goals of Management
Management must be individualized and goes beyond glucose control alone. Key goals include:
- Glycemic targets: HbA1c <7% for most patients (individualized - may be stricter <6.5% in younger, healthier patients or relaxed to <8% in elderly/those with hypoglycemia risk)
- Cardiovascular risk reduction - the leading cause of mortality in T2DM; includes blood pressure control, lipid management, antiplatelet therapy where indicated
- Prevention and monitoring of microvascular complications (nephropathy, retinopathy, neuropathy)
- Weight management - weight loss improves insulin sensitivity
- Medical nutrition therapy (MNT) and exercise are foundational to all stages
Pharmacologic Management
Step 1 - Lifestyle + Metformin (First-line)
Management begins with medical nutrition therapy and exercise. Metformin is the preferred initial pharmacologic agent:
- Reduces hepatic glucose production, modestly improves peripheral glucose utilization
- Reduces fasting plasma glucose and insulin levels; promotes modest weight loss
- Start low, escalate every 1-2 weeks to a maximum tolerated dose of 2000 mg/day
- Monitor vitamin B12 levels (reduced with long-term use)
- Contraindications: GFR <30 mL/min, lactic acidosis risk (liver disease, unstable CHF, severe hypoxemia, radiographic contrast - hold temporarily)
- Harrison's Principles of Internal Medicine, 22nd Ed.
Key Drug Classes for T2DM
| Class | Examples | Mechanism | Key Notes |
|---|---|---|---|
| Biguanides | Metformin | ↓ hepatic glucose production | First-line; weight-neutral to modest loss |
| Sulfonylureas | Glipizide, Glimepiride, Glyburide | ↑ insulin secretion (ATP-K+ channel) | Hypoglycemia risk; weight gain; avoid glyburide in elderly |
| Glinides | Repaglinide, Nateglinide | Same as sulfonylureas (short-acting) | Give before meals; less hypoglycemia |
| GLP-1 Receptor Agonists | Semaglutide, Liraglutide, Dulaglutide, Exenatide | ↑ glucose-stimulated insulin secretion; ↓ glucagon; ↓ gastric emptying | Weight loss; CV benefit in ASCVD; weekly SC or daily oral semaglutide |
| GIP/GLP-1 Dual Agonist | Tirzepatide | Dual GIP + GLP-1 receptor agonist | Greater weight loss than GLP-1 alone; 2025 ADA now recommends for MASLD/MASH |
| SGLT-2 Inhibitors | Empagliflozin, Dapagliflozin, Canagliflozin | ↑ urinary glucose excretion | CV/renal protection; weight loss; DKA risk; UTI/genital infections |
| DPP-4 Inhibitors | Sitagliptin, Saxagliptin | ↑ endogenous GLP-1 by inhibiting degradation | Weight-neutral; generally well tolerated |
| Thiazolidinediones | Pioglitazone | ↑ insulin sensitivity (PPAR-γ) | Weight gain, fluid retention, fracture risk; avoid in CHF |
| Alpha-glucosidase inhibitors | Acarbose | Delays carbohydrate absorption | GI side effects; modest effect |
| Insulin | Various formulations | Direct insulin replacement | Used when oral agents insufficient or at presentation with severe hyperglycemia |
Special Considerations for Drug Selection (2025 ADA Standards)
- Patients with established ASCVD or high CV risk: Prefer GLP-1 RA or SGLT-2 inhibitor with proven CV benefit
- Patients with CKD: SGLT-2 inhibitors (dapagliflozin, empagliflozin) have nephroprotective benefits; GLP-1 RA also reduce diabetic kidney disease
- Patients with heart failure: SGLT-2 inhibitors are preferred (reduce HF hospitalization)
- Patients with obesity: GLP-1 RA (especially semaglutide) or tirzepatide for greater weight reduction
- Patients with MASLD/MASH (metabolic liver disease): GLP-1 RA or dual GIP/GLP-1 agents recommended (new 2025 ADA guidance)
- GLP-1 RAs carry a black box warning for medullary thyroid carcinoma risk (based on rodent data) - contraindicated in personal/family history of MTC or MEN2
Monitoring
| Parameter | Frequency |
|---|---|
| HbA1c | Every 3 months until target, then every 6 months |
| Fasting lipids | Annually |
| Blood pressure | Every visit |
| Urine albumin-to-creatinine ratio | Annually |
| eGFR/serum creatinine | Annually |
| Dilated eye exam | Annually (or per ophthalmologist) |
| Foot exam | Annually + each visit (inspect) |
| Vitamin B12 (if on metformin) | Periodic monitoring |
Complications
Microvascular
- Diabetic nephropathy: Leading cause of end-stage renal disease in the developed world. Starts as microalbuminuria, progresses to macroalbuminuria and reduced GFR. SGLT-2 inhibitors and ACE inhibitors/ARBs are renoprotective.
- Diabetic retinopathy: Leading cause of new adult blindness. Screen annually with dilated fundoscopy. Non-proliferative progresses to proliferative retinopathy - managed with laser photocoagulation or anti-VEGF injections.
- Diabetic neuropathy: Most common is distal symmetric polyneuropathy (glove-and-stocking sensory loss, burning/tingling). Autonomic neuropathy causes gastroparesis, orthostatic hypotension, erectile dysfunction, neurogenic bladder.
Macrovascular
- Accelerated atherosclerosis - coronary artery disease, stroke, peripheral artery disease
- T2DM patients have 2-4x higher CV mortality risk vs. non-diabetics
- Aggressive lipid control (statins, target LDL <70 mg/dL in high-risk patients) and BP control (target <130/80 mmHg) are mandatory
Other
- Diabetic foot - neuropathy + peripheral vascular disease → ulceration, infection, gangrene, amputation
- Hyperosmolar hyperglycemic state (HHS) - life-threatening complication with extreme hyperglycemia (often >600 mg/dL), profound dehydration, altered consciousness, without significant ketoacidosis
- Increased susceptibility to infections (UTIs, skin infections, mucormycosis)
- MASLD/MASH (formerly NAFLD/NASH) - highly prevalent in T2DM due to hepatic insulin resistance
Emerging & Updated Highlights (2025)
- Continuous glucose monitoring (CGM) is now more broadly recommended, even in non-insulin-using T2DM patients
- Tirzepatide (GIP/GLP-1 dual agonist) now explicitly recommended for T2DM with MASLD/MASH
- Updated guidance on GLP-1 RA use in the perioperative setting
- Hospital glucose treatment threshold remains >180 mg/dL; targets 140-180 mg/dL (critically ill) or 100-180 mg/dL (non-critically ill)
- Insulin pump / automated insulin delivery (AID) systems: continue in-hospital when clinically appropriate (new 2025 recommendation)
Summary
T2DM is a progressive disease requiring a stepped, individualized approach combining lifestyle modification, metformin, and escalating pharmacotherapy tailored to comorbidities (heart disease, kidney disease, obesity). Modern drug classes (GLP-1 RAs, SGLT-2 inhibitors) offer benefits beyond glucose control - cardioprotection, nephroprotection, and weight loss - making comorbidity-driven drug selection the current standard of care.
Sources: Harrison's Principles of Internal Medicine, 22nd Ed. (2025), Katzung's Basic and Clinical Pharmacology, 16th Ed., ADA Standards of Care in Diabetes 2025
This is a shared conversation. Sign in to Orris to start your own chat.